

K070857

107

#### 1.4 510(k) Summary of Safety and Effectiveness

Submitted by: Herbert Crane  
Director, Global Regulatory Affairs

Address: Nobel Biocare USA LLC  
22715 Savi Ranch Parkway  
Yorba Linda, CA 92887

Telephone: (714) 282-4800, ext. 7830

Facsimile: (714) 282-9023

Date of Submission: March 27, 2007

Classification Name: Endosseous Dental Implant (21 CFR 872.3640)

Trade or Proprietary  
or Model Name: NobelDirect 3.0 – Immediate Load

Legally Marketed Device(s): NobelDirect (K031345)

DEC 28 2007

Device Description:

Nobel Biocare's NobelDirect 3.0 Implant is a threaded one-piece root form endosseous implant with an integrated abutment designed for one-stage surgical procedures. The NobelDirect 3.0 is 3.0mm in diameter and available in lengths of 13mm and 15mm.

Indications for Use:

The Nobel Direct 3.0mm implant is indicated for use in the treatment of missing maxillary lateral incisors or the mandibular central and lateral incisors to support prosthetic devices, such as artificial teeth, in order to restore chewing function in partially edentulous patients. The NobelDirect 3.0 Implants may be put into immediate function provided that stability requirements detailed in the manual are satisfied.

Mandible central and lateral incisors must be splinted if using two or more 3.0mm implants adjacent to one another.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

DEC 28 2007

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Nobel Biocare AB  
C/O Ms. Phuong Nguyen Son  
Regulatory Affairs Specialist  
Nobel Biocare USA, Incorporated  
22715 Savi Ranch Parkway  
Yorba Linda, California 92887

Re: K070857  
Trade/Device Name: NobelDirect 3.0- Immediate Load  
Regulation Number: 21 CFR 872.3640  
Regulation Name: Endosseous Dental Implant  
Regulatory Class: II  
Product Code: DZE  
Dated: December 10, 2007  
Received: December 11, 2007

Dear Ms. Son:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Shu W. Meng" followed by a stylized signature that likely represents "Chiu Lin, Ph.D.". The signature is written in a cursive, flowing style.

Chiu Lin, Ph.D.

Director

Division of Anesthesiology, General Hospital,

Infection Control and Dental Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

K070857

1.3

**Indications for Use**

510(k) Number (if known):

Device Name: NobelDirect 3.0 - Immediate Load

Indications For Use:

The Nobel Direct 3.0mm implant is indicated for use in the treatment of missing maxillary lateral incisors or the mandibular central and lateral incisors to support prosthetic devices, such as artificial teeth, in order to restore chewing function in partially edentulous patients. The NobelDirect 3.0 Implants may be put into immediate function provided that stability requirements detailed in the manual are satisfied.

Mandible central and lateral incisors must be splinted if using two or more 3.0mm implants adjacent to one another.

Prescription Use  X   
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use \_\_\_\_\_  
(21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

*Shirley R. Murphy MD*

*K 070857*